Application represents an important step in supporting reimbursement Company remains on track for U.S. commercial launch of LYTENAVA before year-end 2026 ISELIN, N.J., Oct. 01, 2026 (GLOBE NEWSWIRE) - ...
SUNNYVALE, Calif., July 13, 2026 -- Embolx, Inc., a leader in advanced microcatheter technology for targeted embolization procedures, today announced that the Centers for Medicare & Medicaid Services ...
ISELIN - Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA (bevacizumab-vikg, bevacizumab gamma) for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results